INDIVIDUAL TEST 965

Titin Antibodies (IgG)

Indication

Suspicion of Myastenia Gravis or paraneoplastic syndrome

Sample material

Serum

• Minim. volume: 0,5 mL

CSF

• Minim. volume: 2,0 mL

Transport

Within Sweden

• room temperature

International

• cold

Method

Immunoblot

Reference interval

Serum

• ≤5 negative

CSF

• negative

Result

Serum

• results are reported as negative, borderline, or positive with an intensity value.

CSF

• results are reported as negative, or positive.

Interpretation

Antibodies against Titin can be detected in patients with Myasthenia Gravis and are associated with thymoma.

References

• Rosenfeld MR, Dalmau J. Neurol Clin. 2018. Paraneoplastic Neurologic Syndromes. PMID: 30072076
• Balint B et al. Brain. 2018. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. PMID: 29053777
• Graus F et al. Neurol Neuroimmunol Neuroinflamm. 2021. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. PMID: 34006622
• Garza M, Piquet AL. Front Neurol. 2021. Update in Autoimmune Movement Disorders: Newly Described Antigen Targets in Autoimmune and Paraneoplastic Cerebellar Ataxia. PMID: 34489848
• Sanders D.B et al. Neurology. 2016. International consensus guidance for management of myasthenia gravis. PMID: 27358333

Last updated: 2024-10-22